Track SOPH and 10,000+ stocks
Create a free account to build watchlists, compare peers, and value any stock.
- Build and track watchlists
- Compare against peers
- Earnings & price alerts
No credit card required
Main
Market Cap$459.55M
Enterprise Value$444.60M
Revenue (TTM)$81.18M
Net Income (TTM)-$80.94M
Free Cash Flow (TTM)-$45.43M
Financial Health
Cash$65.39M
Net Debt-$14.95M
Debt Ratio0.32
Debt to Equity1.1
Interest Coverage-10.37
Valuation (TTM)
Price to Sales5.66
Price to Earnings-5.68
EV to EBITDA-6.73
Price to Book10.06
Price to Free Cash Flow-10.12
Margins (TTM)
Gross Profit Margin67.28%
EBITDA Margin-81.44%
Operating Income Margin-88.39%
Net Income Margin-99.70%
Free Cash Flow Margin-55.96%
Returns (5Y Avg)
Return on Invested Capital-44.83%
Return on Assets-36.45%
Return on Equity-70.99%
Return on Total Capital-44.83%
Return on Capital Employed-44.69%
Dividend Summary
Dividend Yield-
Annual Dividend-
Payout Ratio-
Ex Dividend Date-
5-Year Dividend CAGR-
CAGR (5Y)
Revenue22.16%
Diluted EPS-4.83%
Total Debt63.13%
Capital Expenditures-29.10%
Free Cash Flow-1.66%
CAGR (3Y)
Revenue17.56%
Diluted EPS6.39%
Total Debt165.66%
Capital Expenditures-61.90%
Free Cash Flow1000.00%
CAGR (1Y)
Revenue18.56%
Diluted EPS-17.31%
Total Debt226.91%
Capital Expenditures-92.98%
Free Cash Flow1000.00%
$6.40-$0.10|-1.56%
Last updated: Jul 22, 4:00 PM ET
52W High$6.74
52W Low$2.92
50D SMA$5.28
200D SMA$4.89
Volume493.61K
Sophia Genetics SA
La PiEce 12, Rolle, Switzerland, 1180
IPO
2021
Employees
415
Industry
Health Information Services
Sector
Healthcare
SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. It offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. The company has a partnership with Synnovis to bring blood-based cancer testing to patients in the United Kingdom. The company was incorporated in 2011 and is based in Rolle, Switzerland.
Insider Transactions
Quarterly buy vs. sell activity
Sell (left)Buy (right)
Q2 202620-20
0
Analyst Ratings
2 analysts covering
Buy50%recommend buy
Buy
1
Hold
1
Sell
0